Identification of \textit{COL4A1} as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis

RU HUANG$^{1*}$, WENCHAO GU$^{1*}$, BIN SUN$^2$ and LEI GAO$^1$

$^1$Department of Heart Failure, Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120; $^2$Department of Pharmacy, No. 210 Hospital of PLA, Dalian, Liaoning 116000, P.R. China

Received October 13, 2017; Accepted February 27, 2018

DOI: 10.3892/mmr.2018.8664

\textbf{Abstract.} Trastuzumab, the first targeted antibody against human epidermal growth factor receptor 2 (HER2), has been used to treat gastric cancer patients with HER2 overexpression. However, trastuzumab resistance often occurs following an initial period of benefits, and the underlying mechanisms remain largely unclear. The present study revealed that collagen type IV $\alpha_1$ chain (\textit{COL4A1}), whose expression is upregulated in gastric cancer tissues and trastuzumab-resistant gastric cancer cells, may potentially confer trastuzumab resistance in gastric cancer. By performing bioinformatics analysis of 2 microarray datasets, the present study initially identified \textit{COL4A1}, overexpressed in gastric cancer tissues and trastuzumab-resistant gastric cancer cells, as a potential candidate for inducing trastuzumab resistance. The drug resistance function of \textit{COL4A1} in gastric cancer was then validated by performing protein/gene interactions and biological process annotation analyses, and further validated by analyzing the functionality of microRNAs that target \textit{COL4A1} mRNA. Collectively, these data indicated that \textit{COL4A1} may confer trastuzumab resistance in gastric cancer.

\textbf{Introduction}

Gastric cancer is the third most frequently diagnosed cancer type, and has been the leading cause of cancer-related death in less-developed countries (1). Although advances in therapeutic strategies such as surgery and systemic chemotherapy, have improved the clinical outcomes for gastric cancer patients, the prognosis of these patients remains poor because of frequent cancer recurrence (2). Nevertheless, due to the encouraging development in newly targeted therapies, such a disappointing clinical condition has been improving. Trastuzumab, the first targeted antibody against human epidermal growth factor receptor 2 (HER2), has been approved for the treatment of patients with HER2-positive metastatic gastric cancer (3). However, even with trastuzumab resistance, gastric cancer almost inevitably progresses, as the tumors become resistant to trastuzumab after an initial period of clinical benefits (4). Mechanisms leading to trastuzumab resistance in breast cancer, such as cross-talk between HER2 and other intracellular kinase receptors, have been described recently (5), however, the underlying mechanisms of trastuzumab resistance in gastric cancer remain largely unknown.

Cancer cells are able to activate alternative survival pathways yielding drug resistance in response to chemotherapy, and thereby leads to the chemotherapeutic treatment failure (6). Since drug resistance is a common cause limiting the efficacy of cancer treatment, several mechanisms are elucidated to be responsible for the resistance development, such as increased rates of drug efflux, apoptosis resistance, and microRNAs (miRNAs) mediated overexpression of many drug resistance-related genes (7). Microarray technology, a high-throughput platform that analyzes gene expression, in combination with bioinformatics analysis has been widely used as a promising tool to acquire gene signature during tumorigenesis or drug resistance, and identify prognostic biomarkers in cancer patients (8-10). Abnormal expression patterns of drug resistance-related genes commonly play important roles in drug resistance (11), thus, exploring and identifying the critical drug resistance-related genes based on microarray analysis would have a significant impact.

Therefore, in the present study, we sought to identify the potential genes that promote trastuzumab resistance in gastric cancer through retrieving microarray data from public databases and comprehensive bioinformatics analysis.

\textbf{Correspondence to:} Dr Lei Gao, Department of Heart Failure, Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, 150 Jimo Road, Pudong, Shanghai 200120, P.R. China

E-mail: gldlykdx@163.com

*Contributed equally

\textbf{Key words:} bioinformatics analysis, gastric cancer, trastuzumab resistance, differentially expressed genes, collagen type IV $\alpha_1$ chain
Materials and methods

Microarray data. The gene expression profiles of GSE26899, GSE77346, GSE54129, and GSE65801 were obtained from the Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo). In detail, GSE26899 dataset is consisted of 96 clinical gastric tumor tissues and 12 adjacent normal tissues; GSE77346 dataset is consisted of 1 trastuzumab-sensitive cell line and 4 trastuzumab-resistant cell lines (12); GSE54129 includes 111 human gastric cancer tissues and 21 non-cancerous tissues; GSE65801 contains 32 gastric cancer tissues and 32 paired non-cancerous tissues (13).

Processing of microarray data. The raw microarray data files of the datasets downloaded from the GEO website were subsequently analyzed via using the GEO2R (www.ncbi.nlm.nih.gov/geo/geo2r/), an online tool comparing two or more groups of samples in the same experimental setting (14). False Discovery Rate (FDR) of P-value adjusted (adj. P) to 0.05 and log2FC>1 were set as the cut-off criteria.

Functional and pathway enrichment analyses. Gene ontology (GO) analysis is a commonly used approach for functional studies with three ontologies including biological process, molecular function, and cellular component (15), while Kyoto Encyclopedia of Genes and Genomes (KEGG) is a knowledge base for the systematic study of gene functions (16). To study the functional annotations of differentially expressed genes (DEGs), we next employed Database for Annotation, Visualization and Integrated Discovery (DAVID, david.abcc.ncifcrf.gov) to process the GO and KEGG analyses of DEGs identified in gastric cancer samples. P<0.05 was set as the threshold.

Protein-protein interaction (PPI) network construction and module analysis. The Search Tool for the Retrieval of Interacting Genes (STRING), an online database (string-db.org) designed to evaluate PPI information, covers 9,643,763 proteins from more than 2,000 organisms, which was used to construct the PPI. To evaluate the interactive associations of DEGs identified from GSE26899, we mapped these DEGs to the STRING (version 10.5) database. Confidence score >0.4 was selected as significant. PPI networks were constructed by STRING and visualized by Cytoscape. Subsequently, the plug-in Molecular Complex Detection (MCODE) was employed to screen the modules of PPI networks in Cytoscape with the threshold set as follows: MCODE scores >10.

Survival analysis of collagen type IV α1 chain (COL4A1). To evaluate the association between COL4A1 level and its clinical outcomes, Kaplan-Meier plotter (KM plotter; www.kmplot.com), an online survival analysis tool, was performed. KM plotter is capable of assessing the effect of 54,675 genes on overall survival via using 10,188 cancer samples including 4,142 breast, 1,648 ovarian, 2,437 lung, and 1,065 gastric cancer patients (17). Patients with gastric cancer were separated into high- and low-expression groups according to the level of COL4A1, and the overall survival was then analyzed. The hazard ratio (HR) with 95% confidence intervals and log rank P-value were calculated.

Analysis of COL4A1 by geneMANIA and coremine. GeneMANIA, an online tool (www.genemania.org/), can be used to generate hypotheses of gene function, analyze gene lists, and prioritize genes for functional assays (18). After selecting Homo sapiens from the nine optional organisms, COL4A1 was entered into the search bar and the results were then collected. Annotation of biological processes involving COL4A1 was performed by consulting the Coremine Medical online database (www.coremine.com/medical/).

Prediction of miRNAs. To predict the miRNAs targeting the mRNA of COL4A1, miRWalk (version 2.0, zmf.unum.uni-heidelberg.de/apps/zmf/mirwalk2/), an online platform supplying information about predicted and experimentally validated miRNA-target interactions, was then employed (19). Herein, nine prediction programs (miRWalk, miRanda, miRDB, miRNAMap, Pictar2, PITA, RNA22, RNAhybrid and Targetscan) were selected. These predicted miRNAs were then overlapped by at least seven programs, and selected for further analysis. Pathway enrichment analysis of these miRNAs was performed by using the DIANA-miRPath web server (snf-515788.vm.okeanos.grnet.gr/index.php?r=mirpath) (20).

Statistical analysis. SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used to analyze data. Two tailed Student's t-test was used to compare the two groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Module acquisition based on the DEGs identified in gastric cancer tissues. Drug resistance-related genes identified from in vitro drug-induced resistant models may simply represent transcriptional changes, thus, complementary agents targeting these genes are usually failure to translate into clinical practice (21). Because drug resistance acquisition can arise before the malignant transformation stage (22), the genes playing important roles in tumorigenesis and drug resistance is thereby more likely to be critical for resistance occurrence. Therefore, we first identified 509 DEGs in gastric cancer tissues from the GSE26899 dataset using a 2-fold-change and adj. P<0.05 as the threshold cutoff. Among these DEGs, the expression of these 172 genes was significantly upregulated, while that of 337 genes was significantly downregulated in cancer tissues (Fig. 1A). To explore the potential roles of these significantly upregulated DEGs, GO and KEGG pathway analyses, which can provide valuable insights regarding protein function, were performed (23). As shown in Fig. 1B, GO results showed that these significantly upregulated DEGs were largely associated with extracellular region part, collagen, extracellular matrix, and cell or biological adhesion processes. KEGG results also consistently revealed that these DEGs were highly enriched in extracellular matrix-receptor interaction and focal adhesion pathways (Fig. 1C). Based on further DEGs analysis with the STRING database, the PPI network of these DEGs, which contained 505 nodes and 1,207 edges, was subsequently constructed. Using the MCODE plug-in in Cytoscape, we obtained the module with the highest score (Fig. 2A), and also performed a cluster analysis of these genes in the module.
Figure 1. Identification of DEGs from GSE26899 dataset. (A) Volcano plot of DEGs between gastric cancer tissues and surrounding normal tissues. Red dots represent significantly upregulated DEGs in gastric cancer tissues; green dots represent significantly downregulated DEGs in gastric cancer tissues; gray dots represent no significant difference. P<0.05 and fold-change >2 were regarded as significant. (B) GO analysis of significantly upregulated DEGs in gastric cancer tissues. Top 5 enriched GO categories under ‘biological process’, ‘cellular component’ and ‘molecular function’ were indicated. (C) KEGG pathway enrichment analysis of significantly upregulated DEGs in gastric cancer tissues. Top 5 enriched pathways were indicated. DEGs, differentially expressed genes; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix.

Figure 2. Module with the highest score, obtained based on the DEGs identified from GSE26899 dataset. (A) Module with the highest score generated from the protein-protein interaction network of significantly upregulated DEGs in gastric cancer tissues. (B) Heat map of the 17 genes from the selected module. Red, upregulation; Blue, downregulation; DEGs, differentially expressed genes; COL, collagen; PLOD3, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3; SERPINH1, serpin family H member 1.
6390

Expression of COL4A1, overexpressed in gastric cancer tissues, is also upregulated in trastuzumab-resistant gastric cancer cells. To further explore the potential genes contributing to trastuzumab resistance, we retrieved GSE77346 data, a microarray dataset consisted of one trastuzumab-sensitive gastric cancer cell line and four trastuzumab-resistant gastric cancer cell lines (12). After screening the significantly upregulated DEGs in trastuzumab-resistant cancer cells, COL4A1, one of hub genes in the selected module (Fig. 2A), was also found to be significantly upregulated in trastuzumab-resistant cells (Fig. 3A), suggesting COL4A1 might be important in both tumorigenesis and trastuzumab resistance. Since the gene expression is not always consistent with its protein amount (24), further validation of COL4A1 protein level in clinical gastric cancer tissues is quite necessary. By employing the Human Protein Atlas database, an online tool analyzing protein level from clinical specimens, we observed that COL4A1 was positively expressed in gastric cancer tissue, but negatively expressed in normal gastric tissue (Fig. 3B). Two other datasets, including GSE54129 and GSE65801 were also used to validate the mRNA level of COL4A1, which was indeed significantly upregulated in clinical gastric cancer samples (Fig. 3C and D). To investigate potential regulation mechanisms of COL4A1 in gastric cancer, the genomic alteration of COL4A1 in The Cancer Genome Atlas (TCGA) cohort was analyzed using the cBioPortal (www.cbioportal.org/) (25). As shown in Fig. 3E, the amplification, missense mutation, truncating mutation, and deletion of COL4A1 accounted for 4.3, 4.8, 2.0, and 0.5% of stomach adenocarcinoma cases, respectively. The prognostic value of COL4A1 in patients with gastric cancer was analyzed using the KM plotter according to the low and high expression of COL4A1. As shown in Fig. 3F, the high mRNA level of COL4A1 [HR 1.56 (1.31-1.86)] was associated with poor overall survival of gastric cancer patients. Altogether, these data suggest that COL4A1 is a potential gene candidate that promotes the development of gastric cancer and subsequent trastuzumab resistance.

Drug resistance function of COL4A1 is validated by protein/gene interactions and biological process annotation analyses. As a user-friendly web interface for functional prediction of genes, GeneMANIA has been widely used as an effective tool to predict and explore drug resistance-related genes (18). Accordingly, COL4A1 showed interactions with 20 proteins/genes; among these 6 genes were involved in conferring drug resistance in cancer (Fig. 4A). The mRNA expression of these 6 genes in gastric cancer cells and trastuzumab-resistant gastric cancer cells were also evaluated using the microarray data of GSE77346. As shown in Fig. 4B, the mRNA level of angiopoietin 2 (ANGPT2), COL3A1, COL15A1, and secreted protein acidic and cysteine rich (SPARC) were upregulated in trastuzumab-resistant...
Among these genes, \textit{COL4A1} co-expressed and co-localized with \textit{ANGPT2}, collagen type VI α3 chain (\textit{COL6A3}), and \textit{SPARC}, respectively. It has been reported bevacizumab resistance in glioblastoma and doxorubicin resistance in liver cancer are largely mediated by an enforcement of ANGPT2/TIE2 signaling (26,27). Additionally, overexpression of \textit{COL6A3}, one of the most highly upregulated genes in oxaliplatin and cisplatin resistant ovarian cancer cells, has also been recognized to confer cisplatin resistance in sensitive cancer cells (28). Moreover, the accumulation of intracellular SPARC can drive imatinib resistance in chronic myelogenous leukemia cells (29), and also modulate cisplatin resistance via modulating the Let-7f-1 miRNA/HMGB1 signaling in medulloblastoma cells (30). \textit{COL3A1} and \textit{COL15A1}, two types of fibrillar collagen highly expressed in chemotherapeutic drugs resistant ovarian cancer cells (31), were also exhibited to co-express, share protein domains, and co-localize with \textit{COL4A1} (Fig. 4A). Additionally, \textit{COL4A1} also was co-expressed, shared pathways, and had physical interactions with platelet derived growth factor subunit B (\textit{PDGFB}). Akt/PDGFB-B signaling can regulate Akt, and thus confer the hypoxia-induced cisplatin resistance in liver cancer cells (32). PDGFB may contribute to the resistant phenotype and sustain signaling through MAPK and Akt in breast cancer cells (33). The Coremine Medical database is a freely available online tool for obtaining information on health, medicine, and biology (33); thus, we used this database to annotate the biological process of \textit{COL4A1}. As shown in Fig. 4C, 12 biological processes significantly associated with \textit{COL4A1}, gastric cancer, and drug resistance (P<0.01) were annotated. Considering that the close relationships of \textit{COL4A1} with these processes and the close relationships of the 12 processes with gastric cancer and drug resistance, \textit{COL4A1} might be involved in the development of drug resistance in gastric cancer via its effect on these biological processes. In detail, cell growth related biological processes (including cell growth, cell proliferation, and apoptotic process), gene expression regulation-related (including gene expression, RNA interference, and reverse transcription), and especially, the epithelial-mesenchymal transition (EMT) biological process were identified to be closely associated with the development of \textit{COL4A1} in the gastric cancer drug resistance. Therefore, these results suggest that \textit{COL4A1} may confer drug resistance in gastric cancer via regulating cell growth, gene expression, and in particular, epithelial mesenchymal transition (EMT) processes.

\textbf{Drug resistance function of COL4A1 is further validated by analyzing functionality of miRNAs that target COL4A1 mRNA.} Post-transcriptional gene expression regulated by miRNAs is important for multiple cellular processes during development and pathogenesis (34). Amplification and overexpression of tumor-promoting miRNAs or
Table I. Top 8 enriched pathways regulated by microRNAs that target collagen type IV α1 mRNA and their associations with drug resistance in gastric cancer.

| Author, year | miRNAs (hsa-miR-) | KEGG pathway | P-value | Regulation of drug resistance in cancers (Refs.) |
|--------------|------------------|--------------|---------|-----------------------------------------------|
| Wu et al., 2017 | 29b-3p, 124-3p, 148a-3p, 29a-3p, 152-3p, 148b-3p, 506-3p, 628-5p, 29c-3p, 767-5p, 637, 33a-5p, 33b-5p, 203a, 374a-5p, 300, 106a-5p, 98-5p, 381-3p, let-7b-5p, 7c-5p, 7b-3p, 7a-5p | ECM-receptor interaction | 1.14x10^{-15} | Yes (37) |
| Sun et al., 2017 | | TGF-β signaling pathway | 6.58x10^{-11} | Yes (38) |
| Lanzi et al., 2017 | | Viral carcinogenesis | 9.72x10^{-11} | None |
| Guljar et al., 2017 | | Proteoglycans in cancer | 3.94x10^{-10} | Yes (39) |
| Lee et al., 2015 | | Hippo signaling pathway | 6.66x10^{-10} | Yes (44) |
| Wallerand et al., 2010 | | Cell cycle | 1.01x10^{-9} | Yes (40) |
| - | | Adherens junction | 2.99x10^{-8} | Yes (41) |
| - | | Pathways in cancer | 3.46x10^{-8} | Cancer pathway |

The miRNAs predicted by at least 7 of the 9 prediction tools were submitted to DIANA-miRPath version 3.0 to perform KEGG analysis. miRNA/miR, microRNA; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; TGF, transforming growth factor.

Discussion

In the present study, based on the bioinformatics analysis of two microarray datasets including GSE26899 and GSE77346, COL4A1, which was overexpressed in gastric cancer tissues and trastuzumab-resistant gastric cancer cells, was identified as a potential gene that promotes gastric cancer and trastuzumab resistance. By combining the protein/gene interactions, biological process annotation, and miRNAs-mRNA interaction analyses, we showed that COL4A1 may confer trastuzumab resistance in gastric cancer.

Traditional chemotherapy and newly targeted therapy are two important methods of cancer treatment; however, the clinical efficacy of both is largely limited due to the occurrence of subsequent drug resistance (52). Mechanisms underlying drug resistance, such as alteration of drug targets or metabolism and genetic mutation (11) have been elucidated. Similar to that in breast cancer, the HER2-positive rate in gastric cancer can range from 20 to 42% (53). However, although the benefits of trastuzumab against HER2-positive gastric cancer have been formally established (3,53), trastuzumab resistance is almost inevitable and eventually leads to the therapeutic failure (4). Interfering with the combination of trastuzumab and HER2 (54) and constitutive dimerization of the HER2 receptor (55) have been recognized as causes of trastuzumab resistance. Recently, abnormal expression of tumorigenesis or drug resistance-related genes, such as phosphatidylinositol 3-kinase/Akt signaling (56)
| miRNA-mRNA prediction tools | miRNA/miR, microRNA. | Author, year | miRNA (hsa-) A | miRNA (hsa-) B | miRNA (hsa-) C | miRNA (hsa-) D | miRNA (hsa-) E | miRNA (hsa-) F | miRNA (hsa-) G | miRNA (hsa-) H | miRNA (hsa-) I | Drug resistance-related functions of miRNAs in cancers | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
|-----------------------------|---------------------|--------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|------------------------------------------------|------------------------------------------------|
| miR-29b-3p                  | 1                   | 1            | 1              | 1              | 1              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
| miR-124-3p                  | 1                   | 1            | 1              | 1              | 1              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
| miR-148a-3p                 | 1                   | 1            | 1              | 1              | 1              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
| miR-506-3p                  | 1                   | 1            | 1              | 1              | 1              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
| miR-628-5p                  | 1                   | 1            | 1              | 1              | 0              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
| miR-29c-3p                  | 1                   | 1            | 1              | 1              | 0              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
| miR-767-5p                  | 0                   | 1            | 1              | 1              | 1              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
| miR-637                     | 1                   | 1            | 1              | 1              | 0              | 1              | 1              | 1              | 1              | 1              | Drug resistance‑related genes identified from microarray datasets and employing subsequent bioinformatics analysis, COL4A1 was validated as an important gene that drives trastuzumab resistance in gastric cancer. |
to excessive activation of the PI3K/AKT pathway. A phase 1 clinical trial has been performed to evaluate the efficacy of the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors; interestingly, MK-2206 is safe, and reversed the trastuzumab resistance in HER2-overexpressing patients (70). Collectively, this evidence suggests that identification of drug-resistant genes through bioinformatics methods and subsequent design of small molecule drugs may have great potential.

In conclusion, our results show that COL4A1 may confer trastuzumab resistance in gastric cancer via multiple mechanisms based on bioinformatics analysis. However, further investigations elucidating the drug resistance function of COL4A1 in trastuzumab-resistant gastric cancer models are necessary.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LG conceived the project and designed the research plan. RH and WG performed the experiments and analyzed the data with input from BS who assisted in experimental design and data analyses. RH and LG wrote the manuscript, and all authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Corso S and Giordano S: How can gastric cancer molecular profiling guide future therapies? Trends Mol Med 22: 534-544, 2016.
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawai K, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
4. Aprile G, Giampieri R, Bonotto M, Bittoni A, Ongaro E, Cardellino GG, Graziano F, Giuliani F, Pasola G, Cascini S and Scartozzi M: The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey. Exp Opin Investig Drugs 23: 925-942, 2014.
5. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA and Arteaga CL: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909–4919, 2007.
6. Gottesman MM, Lavi O, Hall MD and Gillet JP: Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol 56: 85-102, 2016.
7. Gianfalo M and Croce CM: MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Update 16: 47-59, 2013.
8. Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, Sun Z, Szoek J, Gerald WL, Watson M, et al: A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3: e467, 2006.
9. Chen F, Xiang CX, Zhou Y, Ao XS, Zhou DQ, Peng P, Zhang HQ, Liu HD and Huang X: Gene expression profile for predicting survival of patients with meningioma. Int J Oncol 46: 791-797, 2015.
10. Kulasingam V and Diamandis EP: Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 5: 588-599, 2008.
11. Yin F, Liu X, Li D, Wang Q, Zhang W and Li L: Tumor suppressor genes associated with drug resistance in ovarian cancer (Review). Oncol Rep 30: 3-10, 2013.
12. Liu G, Carbone C, Cataldi I, Di Nicolantonio F, Giacopuzzi S, Aprile G, Simionato F, Boschi F, Zanotto M, Mina MM, et al: An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients. Clin Cancer Res 22: 6164-6175, 2016.
13. Li H, Yu B, Li J, Su L, Yan M, Zhang J, Li C, Zhu Z and Liu B: Characterization of differentially expressed genes involved in pathways associated with gastric cancer. PLoS One 10: e0125013, 2015.
14. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashasky M, Marshall KA, Philippy KH, Sherman PM, Holko M, et al: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res 41: D991-D995, 2013.
15. Huilsseige I, Kommadath A and Smits MA: Globaltest and GOEAST: Two different approaches for Gene Ontology analysis. BMC Proc 3 (Suppl 4): S10, 2009.
16. Karkanis A and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000.
17. Györffy B, Lándczky A and Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 19: 197-208, 2012.
18. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al: The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38: W214-W220, 2010.
19. Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods 12: 697, 2015.
20. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T and Hatzigeorgiou AG: DIANA-miRPath v3.0: Deciphering microRNA function with experimental support. Nucleic Acids Res 43: W460-W466, 2015.
21. Borst P and Wessels L: Do predictive signatures really predict response to cancer chemotherapy? Cell cycle (Georgetown, Tex) 9: 4836-4840, 2010.
22. Yague E, Arance A, Kubitz La, O’Hare M, Jat P, Ogilvie CM, Hart IR, Higgins CF and Raguz S: Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res 67: 1130-1137, 2007.
23. Xing Z, Chu C, Chen L and Kong X: The use of Gene Ontology terms and KEGG pathways for analysis and prediction of oncogenes. Biochim Biophys Acta 1860: 2725-2734, 2016.
24. Maier T, Guell M and Serrano L: Correlation of mRNA and protein expression in complex biological samples. FEBS Lett 583: 3966-3973, 2009.
25. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer S, et al: The integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pi3, 2013.
26. Labussiere S, Cheneau C, Prahst C, Gallego Pérez-Larraya J, Farina P, Lombardi G, Mokhtari K, Rahimian A, Delattre JY, Eichmann A and Sanson M: Angiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastoma. Cancer Invest 23: 39-44, 2016.

27. Li T, Liu Z, Jiang K and Ruan Q: Angiopoietin2 enhances doxorubicin resistance in HepG2 cells by upregulating survivin and Ref-1 via MSK1 activation. Cancer Lett 357: 276-284, 2013.

28. Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Chen R, Schlom J, Shock T and Morin PJ: Remodeling of the extracellular matrix through overexpression of collagen VII contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3: 377-386, 2003.

29. Panpru N, Dontula S, Khan AA, Herbert E, Ozer H, Chetty C and Lakka SS: miR-let-7i-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells. Cell Signal 26: 2193-2201, 2014.

30. Januchowski R, Zawierucha P, Rucinski M and Zabel M: HER2 testing in melanoma. Curr Opin Oncol 27: 181-187, 2015.

31. Sun C, Wang FJ, Wang HL, Zhang HG, and Deng M, Gao Z and Huang Y: miR-148a and miR-221 regulates intracellular SPARC expression in drug-resistant ovarian cancer cell lines. Oncol Rep 20: 1065-1071, 2008.

32. Wei X, Wang H, Liu Z, Jiang K and Ruan Q: Angiopoietin2 enhances doxorubicin resistance in HepG2 cells by upregulating survivin and Ref-1 via MSK1 activation. Cancer Lett 357: 276-284, 2013.

33. Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, et al.: MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett 329: 91-98, 2013.

34. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Drug resistance: An evolving paradigm. Nat Rev Cancer 13: 714-726, 2013.

35. Albarello L, Pecciarini L and Doglioni C: HER2 testing in gastric cancer. Adv Anat Pathol 18: 53-59, 2011.

36. Price-Schiavi SA, Jepsen S, Li P, Arango M, Radland PS, Yee L and Arlajway KL: Rat (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99: 783-791, 2002.

37. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero G, Zuniga M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al.: microRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett 329: 91-98, 2013.

38. Boyer J, Allen WL, McLean EG, Wilson PM, McCullia P, Moore S, Longley DB, Celdas C and Johnston PG: Pharmacogenic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66: 2765-2777, 2006.

39. Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L and Lii HH: Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes 51: 714-726, 2016.

40. Kalluri R: Basement membranes: Structure, assembly and role in cancer. Front Biosci 13: 267-275, 2008.

41. Sado Y, Kagawa M, Kishiro Y, Sugihara K, Naito I, Seyer JM, Sugimoto M, Oohashi T and Ninomiya Y: Establishment of the rat lymph node model method of epitope-defined monoclonal antibodies recognizes the six different alpha chains of human type IV collagen. J Histochem Cell Biol 104: 267-275, 1995.

42. Kalluri R: Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433, 2003.

43. Miyake M, Hori S, Morizawa Y, Tatsumi Y, Toritsuka M, Ohnishi S, Shimada K, Furuya K, Khadka VS, Deng Y, et al.: Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human uterine carcinoma of the bladder. Oncotarget 8: 36099-36114, 2017.

44. Jin R, Shen J, Zhang T, Liu Q, Liao C, Ma H, Li S and Yu Z: The highly expressed COL4A1 gene contributes to the proliferation and migration of the invasive ductal carcinomas. Oncotarget 8: 58172-58183, 2017.

45. Sulbice L, Rayar M, Desille M, Turlin B, Fautrel A, Bouchier E, Lamas-Gutierrez F, Meunier B, Boudjema K, Clement B and Coullaurau C: Molecular profiling of stroma identities osteopontin as an independent predictor of poor prognosis in intraperitoneal cholangiocarcinoma. Hepatology 58: 1992-2000, 2013.

46. Rahman M, Chan AP, Tang MJ and Tai IT: Correction: A peptide of SPARC inhibits the interaction between caspase8 and Bcl2 to sensitize chemoresistant tumors and enhance their regression in vivo. PLoS One 10: e0127226, 2015.
67. Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, Liu Y, Yu M, Ma Y, Guo N and Shi M: Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget 6: 5072-5087, 2015.

68. Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK and Liu B: Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res 15: R101, 2013.

69. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, et al: CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26: 136-149, 2014.

70. Hudis C, Swanton C, Janjigian YY, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, et al: A phase I study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res 15: R110, 2013.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.